|
|
|
|
Vol. 9, Issue 9, 2527-2543, September 1998
and
*Department of Physiology and
Department of Clinical
Chemistry, Institute of Biomedicine, University of Helsinki, FIN-00014
Helsinki, Finland
| |
ABSTRACT |
|---|
|
|
|---|
Androgen receptor (AR) belongs to the nuclear receptor superfamily and mediates the biological actions of male sex steroids. In this work, we have characterized a novel 130-kDa Ser/Thr protein kinase ANPK that interacts with the zinc finger region of AR in vivo and in vitro. The catalytic kinase domain of ANPK shares considerable sequence similarity with the minibrain gene product, a protein kinase suggested to contribute to learning defects associated with Down syndrome. However, the rest of ANPK sequence, including the AR-interacting interface, exhibits no apparent homology with other proteins. ANPK is a nuclear protein that is widely expressed in mammalian tissues. Its overexpression enhances AR-dependent transcription in various cell lines. In addition to the zinc finger region, ligand-binding domain and activation function AF1 of AR are needed, as the activity of AR mutants devoid of these domains was not influenced by ANPK. The receptor protein does not appear to be a substrate for ANPK in vitro, and overexpression of ANPK does not increase the extent of AR phosphorylation in vivo. In view of this, it is likely that ANPK-mediated activation of AR function is exerted through modification of AR-associated proteins, such as coregulatory factors, and/or through stabilization of the receptor protein against degradation.
| |
INTRODUCTION |
|---|
|
|
|---|
The androgen receptor (AR) mediates the biological actions
of physiological androgens (Quigley et al., 1995
). DNA-bound
transcription factors, such as AR and other nuclear receptors, have
been postulated to stimulate the efficiency of transcription by
affecting directly or indirectly the assembly of basal transcription
factors into the preinitiation complex, thereby increasing the rate of
transcription initiation (Tjian and Maniatis, 1994
; Horwitz et
al., 1996
; Beato and Sanchez-Pacheco, 1996
). However, regulation
of receptor function also involves cross-talk with other signaling
pathways and interactions with other transcription factors and
coregulatory proteins (Beato et al., 1995
). Although nuclear
receptors may contact directly some members of the basal transcription
machinery (Ing et al., 1992
; Blanco et al., 1995
;
Hadzig et al., 1995
; Schulman et al., 1995
;
McEwan and Gustafsson, 1997
) or TATA-binding protein-associated factors (Jacq et al., 1994
; Schwerk et al., 1995
;
Mengus et al., 1997
), they appear to employ preferentially
coregulators to interact with the transcription machinery (Beato and
Sanchez-Pacheco 1996
; Horwitz et al., 1996
). Examples of the
coregulators include RIP-140 (Cavaillés et al., 1995
),
TIF1 (Le Douarin et al., 1995
), TRIP1/SUG1 (Lee et
al., 1995
; vom Baur et al., 1996
), ARA70
(Yeh and Chang, 1996
), CBP/p300 (Chakravarti et al., 1996
;
Hanstein et al., 1996
; Kamei et al., 1996
), and
SRC-1 (Oñate et al., 1995
) and its variants or related
proteins, such as GRIP1, TIF2, AIB1, and TRAM-1 (Hong et
al., 1996
; Voegel et al., 1996
; Anzick et
al., 1997
; Takeshita et al., 1997
). Most of the these
coregulators have been discovered through protein-protein interaction
screening techniques using the ligand-binding domains (LBDs) of nuclear
receptors as target sequences.
Even though the zinc finger region (ZFR) of steroid receptors is
mainly involved in DNA binding and homodimerization, recent evidence
suggests that it also plays an important role in mediating protein-protein interactions with other regulatory proteins (Schena et al., 1989
; Beato et al., 1995
; Starr et
al., 1996
; Lichtarge et al., 1997
; Moilanen et
al., 1998
). In our search for proteins capable of interacting with
AR ZFR, we have identified a nuclear protein kinase, which we termed
ANPK for androgen receptor-interacting nuclear protein kinase. The
catalytic kinase domain of ANPK shares marked similarity with that of
the minibrain gene product, a protein kinase recently
implicated in learning defects associated with Down syndrome (Smith
et al., 1997
), whereas the C-terminal half of this 130-kDa
protein exhibits no apparent sequence homology with other proteins.
ANPK is a functionally active protein kinase. It interacts with AR in a
hormone-dependent manner and activates AR-mediated transcription,
suggesting that ANPK acts as a coregulator of AR function.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Materials
pPB(
285/+32)-LUC is a reporter that contains nucleotides
(nt)
285 to +32 of the rat probasin promoter (Palvimo et
al., 1996
) and pGRE2-E1b-CAT
(pARE2-E1b-CAT in this report) contains two copies of rat
tyrosine aminotransferase glucocorticoid/progesterone/androgen response
element (GRE/PRE/ARE) inserted upstream of the adenovirus E1b TATA
sequence (a gift from Dr. J. Cidlowski, NIEHS, Research Triangle Park,
NC) (Allgood et al., 1993
). pSG5-hPR1 and pHG0 encoding
human PR1 and GR, respectively, were gifts from Dr. Pierre Chambon
(INSERM, Illkirch, France). pSG5-hGR was created by inserting hGR
coding sequence from pGH0 as a BamHI fragment into the
BamHI site of pSG5 (Stratagene, La Jolla, CA). pCB6-WT18A
(WT1) encoding Wilms' tumor gene product was from Dr. Frank J. Rauscher III (Wistar Institute, Philadelphia, PA). pMOR encoding mouse
ER was a gift from Dr. Malcolm G. Parker (Imperial Cancer Research
Fund, London, UK). pG5-CAT contains five Gal4-binding sites in front of
the adenovirus E1b minimal promoter driving the CAT gene (CLONTECH, Palo Alto, CA). The
-galactosidase (
-gal) expression plasmid pCMV
was purchased from CLONTECH. The following mammalian two-hybrid system vectors were used (all from CLONTECH): pM for expressing DBD of
the Saccharomyces cerevisiae Gal4 protein (residues 1-147), pVP16 for expressing the transcriptional activation domain (VP16 AD) of
the herpes simplex virus VP16 protein (amino acid residues 411-456),
pM-VP16 encoding Gal4 DBD-VP16 AD fusion protein and pVP16-CP for
expressing a fusion of VP16 AD to the polyoma virus coat protein.
Testosterone was purchased from Makor Chemicals (Jerusalem,
Israel), and progesterone, dexamethasone, and rabbit myelin
basic protein (MBP) were from Sigma Chemical (St. Louis, MO).
[3H]Acetyl-CoA was purchased from Du Pont-New England
Nuclear (Boston, MA). Luciferase assay reagent, TNT T7-coupled rabbit
reticulocyte system and recombinant human CDC2 kinase complexed with
cyclin B were purchased from Promega (Madison, WI). Recombinant rat
ERK2 and PHAS-I substrate were from Stratagene. PhosphoSpots cellulose strips containing covalently bound peptide substrates for protein kinases were purchased from Jerini Bio Tools (Berlin, Germany). The
yeast two-hybrid system vectors, pVP16 and pLex-a and pLexN-a, based on
pBTM116 (Bartel et al., 1993
) and encoding bacterial LexA
and LexA fused to a SV40 large T antigen nuclear localization signal
N-terminal to the polylinker, respectively, were kind gifts from Dr.
Stanley Hollenberg (Vollum Institute, Oregon Health Sciences University, Portland, OR). Recombinant c-Jun was expressed and affinity
purified as described by Kallio et al. (1995)
. Histone H1
and HMG14 were purified from calf thymus (Palvimo and
Mäenpää, 1988
), and core histones were isolated from
rat thymus. Histone H3 was purchased from Boehringer Mannheim
(Indianapolis, IN), and [
-32P]ATP (3 Ci/mmol) was from
Amersham Life Science (Arlington Heights, IL).
Isolation of Partial cDNAs for AR-interacting Proteins Using a Yeast Two-Hybrid System
Yeast two-hybrid screening of mouse embryo E10.5 cDNA library (a
gift from S. Hollenberg) was used to identify clones that interact with
human AR (hAR) ZFR as described by Hollenberg et al. (1995)
.
LexA fusion expression vector pLex-ZFR (residues 554-644), which uses
LexA as a DNA-binding component, was generated by inserting a PCR
amplified cDNA fragment encoding residues 554-644 of hAR in-frame into
the BamHI/SalI site of pLex-a and used as a bait. The library with random-primed size-selected cDNA inserts (~500 nt)
in pVP16 vector uses a region of herpex simplex virus VP16 as a
transcriptional activator. The yeast strain L40 (MATa trp1-901 leu 2-3, 112 LYS::(lexAop)4-HIS3
URA3:: (lexAop)8-LacZ) was used in the assay. Approximately 2.5 × 107 transformants
were screened for interaction in the presence of 0.5 mM
3-aminotriazole. All clones potentially interacting with AR ZFR were
cured of the bait plasmid and tested against the negative control
plasmids, pLex-a, pLex-Lamin, and pLex-WT1ZF (WT1ZF; Wilms tumor
protein zinc finger residues 312-419) by a mating strategy using AMR70
(MATa his3
200 lys2-801am trp1-901 leu 2-3, 112 URA3::(lexAop)8-LacZ) (Hollenberg
et al., 1995
). Five of the 28 positive clones contained 400-500 nt cDNAs corresponding to overlapping fragments of ANPK. Liquid
-galactosidase assay was performed as described previously (Moilanen et al., 1997
).
cDNA Cloning and Characterization
A rat testis
ZapII cDNA library was screened with
32P-labeled ANPK cDNA corresponding to amino acids 766-920
(ANPK ID) using standard hybridization and high-stringency washing
conditions (Ausubel et al., 1997
). Positive clones were
converted in vivo into pBluescript plasmids according to
manufacturer's instructions. The BLAST program (Altschul et
al., 1990
) was used to search for DNA and protein sequence
homologies in the databases at National Center for Biotechnology
Information.
Plasmid Construction
The rat (r) AR expression vectors, pSGrAR, rAR
46-408,
rAR
641-902, and rAR
46-408/
641-902, were constructed as
previously described (Palvimo et al., 1993
; Ikonen et
al., 1997
), and the hAR expression vector pSG5hAR was constructed
as described by Adeyemo et al. (1993)
. Fusion vectors
containing indicated (in parentheses) amino acids of AR were
constructed as follows: LexA fusion expression vectors, pLex-ZFR-s
(residues 554-628), pLex-LBD (residues 657-919), and pLex-HLBD
(residues 624-919), were generated by inserting PCR-amplified cDNA
fragments of hAR in-frame into the BamHI/SalI
site of pLex-a (pLexN-a for ZFR-s). The pLex-rAR and pM-rAR coding for
full-length rAR-LexA fusions was constructed by transferring rAR
corresponding to the BamHI/PstI fragment from pGEM-3Z-rAR (Moilanen et al., 1997
) into pLex-a and pM.
pLex-WT1-ZF (zinc finger, residues 312-419) was created by inserting a
PCR-amplified cDNA fragment into the BamHI/SalI
site of pLex-a. Glutathione S-transferase (GST) fusion
expression vector for hAR-ZFR has been described previously (Kallio
et al., 1995
).
To construct pFLAG-ANPK(2-1191) and pFLAG-ANPK(159-1191),
PCR-amplified fragments of ANPK cDNA corresponding to amino acids 2-336 and 159-336, respectively, with KpnI sites in the
upstream primers, were digested with KpnI/BamHI
and cloned into the corresponding site of pFLAG-CMV-2 (Kodak IBI,
Rochester, NY), and a cDNA fragment encoding amino acids
337-1191 was subsequently inserted downstream of the BamHI
site. FLAG-ANPK(K226R) mutant containing Lys226 converted
to Arg in the putative ATP-binding site was constructed as pFLAG-ANPK,
but the fragment corresponding to amino acids 159-336 was generated by
the overlapping PCR mutagenesis strategy (Ausubel et al.,
1997
). ANPK(S357A/Y359A) mutant having both Ser357 and
Tyr359 converted to Ala was created as above, but the
overlapping PCR mutagenesis strategy was used to generate a cDNA
fragment corresponding to amino acids 159-644. pFLAG-ANPK(159-772)
was made by replacing a SmaI fragment of ANPK corresponding
to amino acids 417-1191 with a PCR-generated cDNA fragment encoding
amino acids 417-789. pGEX-ANPK and pGEX-ANPK-ID were obtained by
cloning PCR-generated cDNA fragments corresponding to ANPK(159-920)
and ANPK(766-920) into the EcoRI/SalI or
BamHI/SalI site of pGEX-5X-1 expression vector
(Pharmacia, Piscataway, NJ), respectively. The mammalian two-hybrid
expression vector pVP16-ANPK was created by cloning the ANPK(159-920)
fragment from pGEX-ANPK into the EcoRI/SalI site
in pVP16 vector. All constructs were verified by DNA sequencing using
the ALFExpress system (Pharmacia Biotech).
Cell Culture, Transfections, Metabolic Labeling with [32P]Orthophosphate, and Ligand-binding Assays
All mammalian cell lines, except for S115 cells (from Dr. P. Härkönen, University of Turku, Turku, Finland), were
obtained from American Type Culture Collection (ATCC, Rockville, MD)
and maintained according to ATCC's instructions. S115 were cultured as
described by Palvimo et al. (1996)
. Cells were transfected using the calcium phosphate precipitation method as described previously (Palvimo et al., 1993
; Ikonen et al.,
1997
). The cells (1.5 × 106) were plated on a 10-cm
dish 24 h before addition of the precipitate with indicated
amounts of expression and reporter vectors.
-Gal expression plasmid
pCMV
(2 µg/10-cm plate) was used as an internal control for
transfection efficiency. For domain interaction studies (the mammalian
two-hybrid system), CV-1 cells were transfected using DOTAP reagent as
described by Ikonen et al. (1997)
. Eighteen hours after
transfection, the medium was changed to one containing charcoal-stripped 2% (vol/vol) FBS in the presence or absence of
testosterone as depicted in the figure legends. CAT and
-galactosidase activities were assayed as previously described
(Eastman, 1987
; Rosenthal, 1987
; Palvimo et al., 1993
). For
metabolic labeling with [32P]orthophosphate, CV-1 cells
on 10-cm dishes were transfected with 5 µg of pSG5-rAR (or empty
pSG5) along with 15 µg of pFLAG-ANPK(2-1191) (or empty pFLAG-CMV2).
After 48 h, the cells were washed twice with phosphate-free medium
and incubated for 2.5 h in the presence of 0.25 mCi
[32P]orthophosphate in phosphate-free medium supplemented
with 100 nM testosterone and 2% (vol/vol) FBS (Zhou et al.
1995
). Protein concentration was determined using Bio-Rad (Richmond,
CA) reagents according to the manufacturer's instructions. Luciferase
activity was determined with reagents from Promega using a Luminoskan
RT reader (Labsystems, Helsinki, Finland) (Palvimo et al.,
1996
). Whole cell steroid-binding assays were performed as described by
Palvimo et al. (1993)
. Statistical analyses of the data were carried out using two-tailed Student's t test.
Proteins, Antibodies, and Immunoblotting
Histidine-tagged H6-ZFR (residues 554-644 of hAR)
and H6-N-TERM (residues 141-547) and GST-HLBD (residues
624-919) were expressed in bacteria and purified by affinity
chromatography (Palvimo et al., 1996
). Bacterially expressed
GST-ANPK(159-920) and GST-ANPK(766-920) were purified by affinity
chromatography as described (Kallio et al., 1995
), except
that fusion proteins were eluted in a buffer containing PBS (140 mM
NaCl, 20 mM Na-phosphate, pH 7.4), 10% (vol/vol) glycerol, and 10 mM
reduced glutathione. Polyclonal antisera were raised against purified
GST-ANPK(766-920) in rabbits using 50 µg of protein at each
immunization.
Whole cell extracts were prepared as previously described (Ikonen
et al., 1994
). For immunoblot analysis, 15 µg
of cell extracts were fractionated by electrophoresis on polyacrylamide
gels under denaturing conditions (Laemmli, 1970
) and electroblotted
onto Immobilon-P membrane (Millipore, Bedford, MA) or Hybond ECL
membrane (Amersham). Immunocomplexes were visualized using either ECL
Western blotting detection reagents from Amersham or
5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium substrate
system from Zymed according to the manufacturers' instructions.
Protein-Protein Interaction in Vitro
Protein-protein affinity chromatography using purified GST-AR
ZFR (Kallio et al., 1995
) or GST alone bound to Glutathione Sepharose (5 µg protein/40 µl resin) and 10 µl
[35S]methionine-labeled in vitro- translated ANPK was
carried out in a buffer containing 50 mM Tris-Cl (pH 7.8), 150 mM KCl,
0.1% (vol/vol) Nonidet-40, 0.1% (vol/vol) Triton X-100, 5 mM
MgCl2, 0.5 mM EDTA, 10% (vol/vol) glycerol, 50 µM
ZnCl2, 0.1 mM Na-orthovanadate, 0.5 mM phenylmethylsulfonyl
fluoride, 5 µg/ml leupeptin, 10 µg/ml aprotinin, and 5 µg/ml
pepstatin-A in a total volume of 500 µl at 4°C for overnight. The
resin was subsequently washed four times with 1 ml of binding buffer.
Bound proteins were released in the Laemmli sample buffer (Laemmli,
1970
), subjected to electrophoresis under denaturing conditions, and
visualized by fluorography.
Immunocytofluorescence and Immunohistochemistry
CV-1 cells seeded on glass cover slips on 10-cm plastic plates
were transfected using DOTAP reagent with 1 µg of pFLAG-ANPK and 9 µg of pBSIISK (Stratagene) as carrier DNA. Cells were fixed in 4%
(wt/vol) paraformaldehyde in PBS and permeabilized with Triton X-100,
and the ANPK protein was visualized using anti-FLAG M2 monoclonal
antibody (Kodak IBI, 1:50 dilution) or anti-ANPK antiserum (1:500
dilution) and FITC-conjugated goat anti-mouse or anti-rabbit secondary
antibody, respectively (1:200 dilution, Jackson ImmunoResearch
Laboratories, West Grove, PA) or, in double immunofluorescence labeling
for confocal microscopy, using lissamine-rhodamine-conjugated goat anti-mouse secondary antibody. AR was visualized with a polyclonal rabbit antiserum raised against full-length rAR (K183) and
FITC-conjugated goat anti-rabbit secondary antibody as described
previously (Karvonen et al., 1997
).
Rat prostates were frozen on dry ice and stored at
80°C.
Seven-micrometer cryostat sections from Tissue-Tek (Miles, Kankakee, IL)-embedded tissues were fixed in acetone at
20°C and stored at
20°C. After rehydration in PBS, sections were incubated with 0.03%
(vol/vol) hydrogen peroxide in methanol for 30 min at room temperature
to reduce endogenous peroxidase activity and washed extensively in PBS.
Nonspecific binding was blocked by incubating tissue sections for 30 min in 10% normal rabbit serum in PBS or in 1% blocking reagent (DIG
DNA labeling and detection Kit, Boehringer Mannheim) in 100 mM Tris-Cl
and 150 mM NaCl (pH 7.9). Polyclonal ANPK antiserum was used in a
1:1000 dilution and incubated at room temperature for 1 h or at
4°C for 14-16 h. After washing with PBS, biotin-labeled
anti-rabbit-IgG and AB-complex from Vectastain Elite-Kit (Vector
Laboratories, Burlingame, CA) were applied following the
manufacturer's instructions. Peroxidase reaction was carried out with
0.02% (wt/vol) 3-amino-9-ethylcarbazole in 50 mM Na-acetate (pH 5.0)
for 20 min at room temperature.
Immunoprecipitation, Kinase Assays, and Phosphoamino Acid Analysis
Expression plasmids for wild-type or mutant FLAG-tagged ANPK
were used to transfect CHO cells using the calcium phosphate method.
Two days after transfection, the medium was removed and cell monolayers
washed twice with cold PBS. For immunoprecipitation, cells were lysed
in ice-cold buffer containing 25 mM HEPES (pH 7.5), 100 mM NaCl, 50 mM
NaF, 5 mM EDTA, 1 mM dithiothreitol, 20 mM
-glycerophosphate, 40 mM
p-nitrophenyl phosphate, 0.1 mM Na3VO4, 0.5 µM okadaic acid, 0.5% Triton
X-100, and the following protease inhibitors: 0.5 mM PMSF, 5 µg/ml
leupeptin, 5 µg/ml pepstatin A, and 10 µg/ml aprotinin. The
collected cell debris and lysate were clarified by centrifugation for
15 min at 16,000 × g at 4°C and subjected to
preclearing with normal rabbit serum and GammaBind G Sepharose or
Protein A Sepharose (Pharmacia Biotech). AR from [32P]orthophosphate-labeled cells was immunoprecipitated
with K183 antiserum using Protein A Sepharose and washed three times
with lysis buffer. ANPK was precipitated by incubating lysate with M2
monoclonal antibody (Kodak IBI) (directed against the FLAG epitope) and
GammaBind G Sepharose. For immune kinase complex assays,
immunoprecipitates were washed three times with lysis buffer and twice
with kinase buffer containing 25 mM HEPES (pH 7.5), 10 mM
MgCl2, 0.1 mM Na3VO4, 20 mM
-glycerophosphate, and 1 mM dithiothreitol. For catalytic kinase
assay, immunoprecipitation pellets or bacterially expressed
GST-ANPK(159-920) were incubated with indicated concentrations of
substrates and 35 µM [
-32P]ATP in 20 µl of kinase
buffer. The kinase reaction was performed at 30°C for 30 min and
terminated with 20 µl of 2× Laemmli sample buffer, and the products
were resolved by PAGE under denaturing conditions.
Phosphorylated proteins obtained from the immune complex kinase assays
were transferred electrophoretically to PVDF membranes. The bands
containing phosphoproteins were excised and hydrolyzed in 6 M HCl at
105°C for 75 min. The supernatants were lyophilized and dissolved in
10 µl of H2O containing cold phosphoserine,
phosphothreonine, and phosphotyrosine (0.1 µmol each) as markers.
Phosphoamino acids were resolved by electrophoresis (30 mA, 45 min) at
pH 2.5 (Jelinek and Weber, 1993
).
RNA Isolation and Northern Blot Analysis
RNA was extracted from adult rat tissues by the LiCl-urea
precipitation method (Auffray and Rougeon, 1980
) and enriched for poly(A)+ RNA by oligo(dT)-cellulose chromatography.
Polyadenylated RNA samples (5 µg/lane) were fractionated on 1.3%
agarose gels containing 2.2 M formaldehyde, transferred to Hybond-N
nylon membrane (Amersham), and immobilized onto the membrane by
exposure to UV light (Stratalinker, Stratagene). Membrane was
hybridized to 32P-labeled ANPK cDNA, washed at high
stringency (0.2× SSC, 0.1% SDS, 52°C), and subjected to
autoradiography. Human multiple tissue Northern blot (CLONTECH) was
hybridized according to manufacturer's protocol, washed at high
stringency (0.1× SSC, 0.1% SDS, 35°C), and subjected to
autoradiography.
| |
RESULTS |
|---|
|
|
|---|
Isolation of cDNAs for ANPK
The yeast two-hybrid system was used to identify proteins that
interact with the ZFR of hAR. A fusion between LexA protein and ZFR,
including part of the hinge region (LexA-ZFR, amino acids 554-644 of
hAR), was used as a bait to screen a mouse cDNA library fused to VP16
activation domain (VP16 AD) (Hollenberg et al., 1995
). Five
of the positive clones that interacted specifically and reproducibly
with AR ZFR shared overlapping cDNA sequences of a previously
uncharacterized protein, termed ANPK in this report.
A rat testis cDNA library was screened to isolate longer cDNA clones
than those in the initial screening of the 10.5-d mouse embryo cDNA
library (Hollenberg et al., 1995
). The longest clone of 4120 nt in size contained an open reading frame for 1191 amino acid residues
with a predicted molecular size of 130 kDa for the translated protein
(Figure 1A). The cDNA clone included 471 nt of 5'-untranslated region (UTR) that was GC-rich and 74 nt of 3'-UTR
containing a potential polyadenylation signal (AAUAAA). There was an
in-frame stop codon 9 nt upstream of the first AUG, suggesting that the
cDNA clone was likely to encode a full-length protein.
|
The N-terminal region of ANPK (residues 197-526) showed extensive
sequence homology to many protein kinases, and all of the 12 subdomains
common to known protein kinases were conserved within ANPK (Hanks and
Quinn, 1991
; Hanks and Hunter, 1995
) (Figure 1B). Sequence alignments
also predicted that ANPK is specific for Ser and Thr residues, as
sequences of subdomains VIB and VIII matched with a Ser/Thr-specific
but not a Tyr-specific consensus sequence (Figure 1B). However, whether
ANPK represents a new dual specificity kinase cannot be predicted on
the basis of primary sequence alone (Hanks and Hunter, 1995
).
Comparison of the kinase domain sequence of ANPK with those available
in current data resources indicated that it has greatest similarity to
protein kinases of the Clk subfamily (Hanks and Quinn, 1991
; Hanks and
Hunter, 1995
) but is not a counterpart of any particular member. Among
the characterized protein kinases, ANPK shares highest similarity with
the kinase domain of Yak1 (Garrett and Broach, 1989
) from yeast
and that of Drosophila minibrain (Tejedor et al.,
1995
) or its human and rat homologs, MNB and Dyrk, respectively
(Kentrup et al., 1996
; Shindoh et al., 1996
).
ANPK and Dyrk are 39% identical throughout the kinase domain (Figure
1B), whereas the degree of identity between ANPK and Yak1 catalytic
domains is 43%, and ANPK and Clk1 share 32% identity. Also C. elegans chromosome III appears to encode a protein kinase whose
catalytic domain shares 63% identity with that of ANPK (Wilson
et al., 1994
). The extreme N-terminal region and the
C-terminal half of ANPK seem unique, as sequences outside the kinase
domain do not contain any known functional motifs or share homology
with previously characterized proteins.
Expression and Localization of ANPK
RNA blot analyses revealed expression of ~7 kilobase (kb) ANPK mRNA in many rat tissues (Figure 2A). Two additional smaller ANPK mRNA species, ~4 kb and 2 kb in size, were expressed to very high levels in rat testis. It is currently unknown whether these smaller mRNA species originate from alternative splicing of the primary transcript or the use of a testis-specific promoter. An 8-kb ANPK mRNA was detected in various human tissues; in addition, human testis contained smaller ANPK mRNA species, even though their relative abundance was not as high as in rat testis (Figure 2B). Dot blot analysis revealed the highest levels of ANPK mRNA in human skeletal muscle and heart (our unpublished data). The level of ANPK protein was examined by immunoblot analysis of lysates from several cell lines using a rabbit antiserum raised against bacterially expressed GST-ANPK(766-920). ANPK appeared to be widely expressed, and a ~160-kDa protein comigrating with ANPK produced by translation in vitro was detected in all cell lines examined, including CV-1 cells (Figure 2C).
|
Subcellular localization of ANPK was initially assessed in cultured cells by indirect immunofluoresence using affinity-purified anti-ANPK antibodies. Even though no nuclear localization signal was apparent in the ANPK sequence, transiently expressed ANPK resided almost exclusively in nuclei of CV-1 cells and displayed a speckled pattern of distribution (Figure 3, A and B). Additionally, the endogenous nuclear ANPK of mouse S115 cells, which also express AR protein, exhibited a similar punctate pattern (Figure 3C). In rat prostate, ANPK antigen was detected in nuclei of secretory epithelial cells that exhibited a granular staining pattern with a few ANPK-positive granulae per nucleus (Figure 3, E and F).
|
Protein Kinase Activity of ANPK
To verify that ANPK was indeed a protein kinase, FLAG-tagged
ANPK(159-1191) produced in CHO cells was subjected to immune complex kinase assays using myelin basic protein (MBP) as the substrate. Immunopurified ANPK(159-1191) efficiently phosphorylated MBP (Figure 4A, lane 1), whereas no
incorporation of 32P into MBP was observed in the absence
of kinase (lane 2). As a control, we expressed ANPK(K226R) in which
Lys226 in the consensus ATP-binding site was converted to
Arg. ANPK(K226R) was catalytically inactive, indicating that the ANPK
kinase activity was not due to coimmunoprecipitated or contaminating
proteins (Figure 4A, lane 3). Similar to Yak1 or Dyrk (Garrett et
al., 1991
; Kentrup et al., 1996
), ANPK was
autophosphorylated (Figure 4B, lanes 2 and 3), whereas
ATP-binding-deficient ANPK(K226R) failed to show autophosphorylation
(Figure 4B, lanes 1 and 4). ANPK was also autophosphorylated in
vivo (our unpublished data). Additionally, residues 159-920 of
ANPK expressed as a GST fusion protein in E. coli underwent
autophosphorylation and behaved as an active MBP-phosphorylating kinase
in vitro (Figure 4C).
|
To characterize further the kinase activity of ANPK, histones, a nonhistone protein HMG14, and c-Jun were used as model substrates under cell-free conditions. GST-ANPK was able to phosphorylate c-Jun and histone H3, albeit less efficiently than MBP (Figure 4D). Other core histones, linker histone H1, and HMG14, which are all very basic proteins and good in vitro substrates for many Ser/Thr protein kinases, were not modified by ANPK (Figure 4D and our unpublished data). Solid-phase phosphorylation of a set of recognition sequence peptides for various well-characterized protein kinases revealed that ANPK is not a proline-directed kinase, as could have been anticipated on the basis of efficient phosphorylation of MBP (Figure 4F). ANPK prefers phosphoacceptor sites in the vicinity of or, especially, surrounded by basic amino acids: protein kinase C recognition peptide AAKIQASFRGHMARKK served as the most efficient substrate. Ser or Thr residues embedded in an acidic surrounding, such as peptides RRREEETEEE and RRRDDDSDDD, were very poor substrates. Interestingly, ANPK appears to be capable of transferring phosphate also to Tyr residues in basic peptides, as EAIYAAPFAKKK peptide was phosphorylated. Taken together, these data indicate that the substrate specificity of ANPK differs from those of previously characterized cyclin-dependent kinases (cdks) and MAP kinases.
The major phosphorylation sites of AR appear to be proline-directed,
but the kinase(s) phosphorylating them is (are) unknown (Zhou et
al., 1995
; Blok et al., 1998
). Even though the above results do not imply that ANPK prefers phosphoacceptor sites located close to prolines, AR was still considered as a potential ANPK substrate. However, neither immunopurified FLAG-ANPK nor recombinant GST-ANPK phosphorylated AR in vitro independent of the receptor preparation used as a substrate, including full-length AR expressed and
purified from insect cells (Kallio et al., 1995
), and
bacterially expressed and purified H6- or GST- fusion
proteins corresponding to various functional domains of AR
(Figure 5A and our unpublished data).
Nevertheless, H6-AR fusion protein containing the receptor N-terminal residues 141-547, which encompass the transcription activation function AF1, served as an excellent in vitro substrate for
extracellular signal-regulated kinase 2 (ERK2) with an efficiency better than the established ERK2 substrate PHAS-I (Figure 5A, lanes 5 and 7). Also cyclin B-activated CDC2 kinase phosphorylated the
N-terminal AR domain (lane 11). In keeping with the above data, the
extent of phosphorylation of full-length AR protein was not altered by
coexpression of ANPK CV-1 cells, as judged by 32P
incorporation into immunoprecipitated AR (Figure 5B). Collectively, these results argue against AR being a substrate for ANPK.
|
A series of FLAG-tagged ANPK mutants (Figure
6A) was generated to examine the
importance of different regions of ANPK for its kinase activity.
Full-length ANPK phosphorylated MBP approximately to the same
extent as N-terminally truncated ANPK(159-1191) or ANPK(159-789)
variant that lacked most of the AR-interaction domain (Figure 6B). The
activity of many Ser/Thr kinases and all known MAP kinases is regulated
by either autophosphorylation or trans-phosphorylation within the
activation segment in the catalytic subdomain VIII (Johnson et
al., 1996
). The putative activation segment of ANPK contains
Ser357 and Tyr359 residues as potential
autophosphorylation sites. Both residues were converted to Ala yielding
the ANPK(S357A/Y359A) mutant. These substitutions attenuated ANPK
kinase activity. However, ANPK(S357A/Y359A) was autophosphorylated to
the same extent as full-length ANPK and ANPK(159-1191), whereas the
C-terminally truncated form of the kinase, ANPK(159-789), exhibited no
autophosphorylation (Figure 6C). The catalytic Asp322 in
the subdomain VIB of ANPK is preceded by an Ala, and our data thus
agree with the notion that phosphorylation is not required for
activation of the kinases in which an Arg does not precede the
conserved catalytic Asp (Johnson et al., 1996
). Together, these results indicate that ANPK is not autophosphorylated at the
putative activation segment and that autophosphorylation of this kinase
is not a prerequisite for its catalytic activity in vitro.
|
Phosphoamino acid analysis of MBP and c-Jun phosphorylated by GST-ANPK(159-920) as well as that of autophosphorylated full-length ANPK and ANPK(S357A/Y359A), yielded only phosphoserine and phosphothreonine in each case, confirming that ANPK functions as a Ser/Thr kinase (Figure 6D).
ANPK Interacts with AR in Yeast and Mammalian Cells and under Cell-free Conditions
On the basis of sequences of the five ANPK clones obtained from the two-hybrid screen in yeast, residues 766-920 in the C-terminal region of ANPK appear to be sufficient for the interaction with AR. To characterize this interaction in more detail, full-length AR, AR ZFR without the hinge region residues 624-644 (ZFR-s), and a construct containing LBD and the hinge region (HLBD, residues 624-919 of hAR) were used to generate LexA-AR, LexA-ZFR-s, and LexA-HLBD fusion proteins. These proteins were expressed in yeast together with VP16 AD fused to amino acids 766-920 of ANPK (VP16-ANPK-ID). The interaction between full-length AR and VP16-ANPK-ID was androgen-dependent (Figure 7A). Unliganded AR may be unable to associate with ANPK due to steric hindrance presented by the hormone-free LBD or association of apo-AR with heat-shock proteins and/or other chaperones. Deletion of the hinge region residues from LexA-ZFR reduced markedly the interaction, and ANPK interacted only weakly with LexA-HLBD even in the presence of androgen (Figure 7A). Thus, in addition to the two zinc fingers, sequences in the hinge region are required for the interaction with ANPK.
|
To determine whether AR interacts with ANPK also in mammalian cells, two-hybrid protein-protein interaction assays were carried out in CV-1 cells. Cotransfection of the cells with a Gal4-AR construct, full-length AR fused to the DNA-binding domain (DBD) of Gal4, and a plasmid encoding ANPK(159-920) fused to VP16 AD (VP16-ANPK) elicited a marked and androgen-dependent activation of the reporter gene, indicating hormone-enhanced recruitment of ANPK by AR (Figure 7B). When VP16 AD fused to polyoma virus coat protein (VP16-CP) was used instead of VP16-ANPK, only minimal reporter gene activity was observed in the presence of testosterone (Figure 7B).
Interaction of ANPK with AR under cell-free conditions was assessed by determining the ability of AR ZFR (residues 554-644) as a GST fusion protein to bind 35S-labeled ANPK(1-1191). A significant proportion of the input ANPK was retained on the GST-AR ZFR resin, whereas no binding on the control GST resin was observed (Figure 7C). Moreover, 35S-labeled luciferase did not adsorb onto GST-AR ZFR, verifying the specificity of the interaction between ANPK and AR ZFR (our unpublished data).
ANPK Colocalizes with AR in Mammalian Cells
To assess whether ANPK and AR potentially interact in vivo, their colocalization was studied by a double immunofluorescence labeling technique followed by analysis with a confocal microscope. As already mentioned above, ANPK forms nuclear dot-like structures when transfected into CV-1 cells (Figure 3, A and B, and Figure 8A). We examined, therefore, whether cotransfection of AR with ANPK resulted in both proteins colocalizing to these subnuclear structures. As shown in Figure 8, subnuclear distribution of AR does exhibit the same pattern as that of ANPK. Superimposition of the images of ANPK and AR indicated that the majority of the two proteins had indeed colocalized. Transfection of AR alone did not show such a staining pattern: rather, it displayed a uniform nuclear distribution, suggesting that AR was recruited to nuclear dots by ANPK (our unpublished data). Our preliminary data also suggest that AR and ANPK colocalize in mouse mammary tumor S115 cells, which express relatively high levels of the two proteins.
|
ANPK Enhances AR-dependent Transcriptional Activation
Transient transfection assays were used to examine consequences of
ANPK overexpression on AR-dependent transcription. CV-1 cells were
cotransfected with vectors encoding ANPK(159-1191) and rAR together
with a reporter gene (luciferase) driven by the probasin promoter
regulated by AR. Ligand-free rAR had minimal activity both in the
absence and presence of ANPK (Figure 9A). The presence of androgen stimulated rAR activity
10-fold, and increasing amounts of coexpressed ANPK further activated AR function by
three- to fourfold, whereas the kinase-negative ANPK(K226R) hardly
influenced it (Figure 9A). The kinase-negative ANPK(K226R) inhibited
the function of wild-type ANPK by 55 ± 6%, when the two proteins
were coexpressed in a 3:1 ratio. ANPK did not modulate the antagonistic
activity of the nonsteroidal antiandrogen casodex (our unpublished
data). Very similar results were obtained in PC-3 and CHO cells. ANPK
augmented AR-dependent transcription also from a minimal promoter
containing two androgen response elements (AREs) in front of the E1b
TATA sequence (pARE2-E1b-CAT) (see Figure
10B). It is of special interest that
ANPK did not modulate the transcriptional activity of glucocorticoid
receptor (GR) or progesterone receptor (PR) on
pARE2-E1b-CAT expression under the same conditions (Figure
9, B and C).
|
|
AF1 and LBD Are Also Required for ANPK to Activate AR Function
To identify the domains of AR that are critical for the activation
by ANPK, various AR deletion mutants were investigated (Figure 10A). In
addition to full-length AR, ANPK activated markedly the function of
AR
40-147 lacking residues 40-147, whereas the function of two
constitutively active AR forms, AR
641-902 and AR
46-408/
641-902, was barely influenced by coexpressed ANPK (Figure 10B). It is also noteworthy that ANPK did not activate a
transcriptionally silent AR mutant, AR
46-408, devoid of activation function AF1 (Ikonen et al., 1997
). These results indicate
that the presence of both AF1 and LBD is required for ANPK to activate AR function.
ANPK Domains Needed to Activate AR Function
Several ANPK constructs (see Figure 6A) and AR were coexpressed in CV-1 cells, and their ability to activate AR-regulated probasin promoter was compared with that of ANPK(159-1191) (set as 100%). The activity of full-length ANPK(2-1191) did not differ markedly from that of ANPK(159-1191) (relative activity 82 ± 12% vs. 100 ± 9%). ANPK(159-772) that lacks most of the AR-interacting interface and ANPK(S357A/Y359A) exhibited both less than half of the activity of ANPK(159-1191) (35 ± 6% and 45 ± 9%, respectively). Diminished activity of ANPK(159-772) implies that the interaction between AR ZFR and ANPK is indeed important for ANPK to activate AR function. That ANPK(159-772) retained a modest activity on AR function can be explained by its remaining ability to phosphorylate some target substrates. Marked reduction in the activity of ANPK(S357A/Y359A) was not surprising, as the mutations in the putative activation segment also influenced its catalytic protein kinase activity.
Influence of ANPK on Cellular AR Concentration
To investigate whether ANPK influences the amount of AR,
immunoreactive AR content and cellular androgen-binding capacity were
analyzed in the presence and absence of cotransfected ANPK. There was a
~2-fold increase in the amount of immunoreactive AR protein in
samples derived from CV-1 cells expressing ANPK, whereas the amount of
AR
641-902 devoid of LBD was not significantly influenced by
coexpressed ANPK (Figure 11). Increased
amount of immunoreactive wild-type AR antigen was consistent with
~2.5-fold elevated androgen-binding capacity, as assessed by whole
cell ligand-binding assays (AR + ANPK, 87, 520 ± 5470 receptors/cell vs. AR alone, 33,120 ± 2660 receptors/cell). ANPK
did not increase the amount of AR mRNA and thus, it does not activate
the promoters used to drive AR expression plasmids or stabilize AR
mRNA. Together, these data suggest that ANPK-AR interaction stabilizes
AR protein and, in addition to ZFR, LBD is needed for the stabilization
to take place.
|
| |
DISCUSSION |
|---|
|
|
|---|
We have characterized in this work a novel Ser/Thr protein kinase,
ANPK, which interacts with the AR. ANPK is a nuclear protein and widely
expressed in human and rat tissues. The catalytic domain of ANPK is
39% identical with that of the rat minibrain gene product, a protein kinase whose Drosophila homologue is involved in
postembryogenic neurogenesis (Tejedor et al., 1995
). The
human homologue of the minibrain gene was recently
implicated in learning defects associated with Down syndrome (Smith
et al., 1997
). The kinase domain of ANPK also shows
extensive similarity with Yak1 from Saccharomyces cerevisiae
(Garrett and Broach, 1989
). While this manuscript was being
finalized for publication, the human counterpart of ANPK, termed
putative protein kinase Y (PKY), was deposited to the GenBank (Begley
et al., 1997
). PKY comprises 1,215 residues and is 91% identical with ANPK. Expression of PKY mRNA was shown to be elevated in
some multidrug-resistant cell lines, and PKY was postulated to play a
role in the development of multidrug resistance (Begley et
al., 1997
).
The physiological substrates of Yak1 and MNB are not known. According
to Hanks and Hunter (1995)
, Yak1 belongs to the Clk family in the CMGC
group of protein kinases made up also by cdk, MAP kinase, and
GSK3
/CK2 families. ANPK is likely to represent a new member of this
protein kinase group. Our results show that the substrate specificity
of ANPK is distinguishable from those of cdk and (ERK) MAP kinases.
Extensive sequence similarity between ANPK and two cDNA fragments of
homologous protein kinases also found in our two-hybrid screen
(our unpublished results) suggests the existence of an
additional subfamily of Ser/Thr protein kinases. Like MNB and Yak1,
ANPK encompasses a distinct N-terminal domain, a kinase core domain and
a characteristic C-terminal domain. Despite the similar molecular
design of these kinases, the N-terminal and the long C-terminal domains
of ANPK appear unique and share no significant homology with Yak1, MNB,
or any other characterized protein kinase. Similar to the
minibrain gene product (Song et al., 1997
), both
transiently expressed and endogenous ANPK protein resides in the
nuclear compartment of cells.
The activity of transcription factors is frequently regulated by
multiple phosphorylation and dephosphorylation events (Hunter and
Karin, 1992
; Hill and Treisman, 1995
). Furthermore, steroid receptors
are phosphoproteins, and many of them become hyperphosphorylated upon
hormone binding, suggesting that there is a link between the
phosphorylation status and the activation state of these receptors (Weigel, 1996
). Activation of signal transduction cascades by kinase
and phosphatase modulators can stimulate transcriptional activity of
many steroid receptors, including AR, estrogen receptor (ER), GR, and
PR (Beck et al., 1992
; Somers and DeFranco, 1992
; Cho and
Katzenellenbogen, 1993
; Moyer et al., 1993
; Ikonen et al., 1994
). Selective activation of extracellular signal-regulated kinases can also inhibit GR-mediated transcriptional activation (Rogatsky et al., 1998
). In addition, various steroid
receptors, such as human and rat ER, chicken PR, and human AR, may be
activated in a ligand-independent manner by growth factors,
neurotransmitters, and other compounds that modulate intracellular
phosphorylation and/or dephosphorylation events (Denner et
al., 1990
; Power et al., 1991
; Culig et al.,
1994
; Nazareth and Weigel, 1996
). Mutagenesis experiments on the major
phosphorylation sites of steroid receptors have, however, yielded
contradictory results about the biological significance of receptor
phosphorylation (Weigel, 1996
).
Ligand-independent activation of chicken PR has been postulated to be
mediated through changes in the phosphorylation of coregulatory proteins rather than in the receptor itself (Bai et al.,
1997
). By contrast, EGF signaling through the MAP kinase pathway
induces phosphorylation of Ser118 in human ER, which
results in the activation of this receptor in the absence of hormone
(Kato et al., 1995
; Bunone et al., 1996
). A
specific Tyr phosphorylation site is present within the
carboxyl-terminal AF2 domain of ER (Arnold et al., 1997
),
and replacement of this residue with a charged amino acid or an Ala
generated activated receptors that bound coactivator proteins in a
ligand-independent manner (White et al., 1997
).
Collectively, these results emphasize that coregulatory proteins
themselves and their interactions with steroid receptors are both
likely to be regulated by protein phosphorylation events.
AR is phosphorylated on multiple sites, but nothing has been reported
about the kinases involved (Zhou et al., 1995
; Blok et
al., 1998
). Our current results indicate that both ERK2 and CDC2
are among the kinases that potentially regulate AR function through
direct phosphorylation of the receptor protein. Interestingly, both of
these kinases have recently been demonstrated to phosphorylate GR and
thereby modulate its transcriptional activity (Krstic et al., 1997
). Despite the physical interaction between ANPK and the
receptor, AR was not phosphorylated by ANPK under cell-free conditions,
and overexpression of the kinase did not increase the extent of AR
phosphorylation in intact cells. Moreover, rAR
40-147, devoid of the
two potential phosphorylation sites of rAR (Ser61 and
Ser75, corresponding to Ser81 and
Ser94 residues of hAR) and a hAR mutant in which the third
phosphorylation site, Ser650 (Zhou et al.,
1995
), was replaced by an Ala were both stimulated by ANPK in a manner
similar to wild-type AR (Figure 10 and our unpublished results),
supporting the notion that ANPK function does not involve direct
phosphorylation of AR protein.
If ANPK does not indeed employ AR as the substrate, how might it then
activate AR-dependent gene transcription? A modest increase in the
receptor protein concentration in response to ANPK overexpression may
not suffice. Anchoring of ANPK to AR would enable the kinase to recruit
specific substrate proteins that are AR-associated proteins/coregulators, components of the transcriptional machinery, or
chromatin structural proteins, such as histones. Phosphorylation of
these proteins could subsequently enhance their interactions with the
receptor or stabilize multiprotein complexes. While ANPK interacts with
AR ZFR, the requirement of LBD for ANPK to activate AR-dependent
transcription could be explained through a mechanism, in which ANPK
phosphorylates a coactivator that interacts with LBD. Indeed, most of
the recently characterized nuclear receptor coregulatory proteins seem
to function through ligand-dependent interaction with the AF2 region in
LBD (Horwitz et al., 1996
). ANPK may also be involved in
stabilization of the interaction between amino- and carboxyl-terminal
regions of AR, an event known to be influenced by some other
coregulatory proteins (Ikonen et al., 1997
). ANPK showed
strict substrate selectivity for nucleosomal core histones and
catalyzed only phosphorylation of histone H3, a phenomenon that was
recently suggested to be restricted to a small
hyperacetylation-sensitive fraction of nucleosomes (Barratt et al., 1994
). Therefore, it is tempting to speculate that
ANPK is involved in the rearrangement of nucleosomes in promoter
regions regulated by the AR.
ANPK did not activate PR and GR function under the experimental
conditions used in this work, indicating that, even though many
coregulators are shared by nuclear receptors (Horwitz et al., 1996
), there is some receptor specificity among them. Action of cyclin D1 provides another example of receptor specificity: cyclin
D1 is able to activate ER in a cdk-independent manner without exerting
this action on other steroid receptors (Zwijsen et al., 1997
). Moreover, activation differences between steroid receptors have
been demonstrated in yeast cells expressing mutant forms of Hsp90 and
Cdc37p (Bohen and Yamamoto, 1993
; Fang et al., 1996
; Fliss
et al., 1997
). Hsp90 was not phosphorylated by ANPK in vitro and thus not likely to play a role in ANPK-mediated activation of AR
function (our unpublished observations).
Several nuclear receptor coregulators characterized over the last few
years possess enzymatic activity, in that some catalyze acetylation of
histones (Montminy, 1997
; Perlmann and Evans, 1997
) or even
transcriptional activators (Gu and Roeder, 1997
), whereas others are
involved in deacetylation of histones (Pazin and Kadonaga, 1997
;
Perlmann and Evans, 1997
). ANPK is a functionally active Ser/Thr
kinase, and it appears to be the first putative steroid receptor
coregulatory protein that catalyzes protein phosphorylation. However,
to understand better the biological importance of ANPK, its
physiological substrates should be identified and mechanisms controlling its catalytic activity clarified.
| |
ACKNOWLEDGMENTS |
|---|
The authors thank Ms. Leena Pietilä, Pirjo Kilpiö, and Seija Mäki for excellent technical assistance; Drs. P. Chambon, J.A. Cidlowski, M.G. Parker, and F.J. Rauscher III for plasmids; Dr. S.M. Hollenberg for providing the materials for the yeast two-hybrid system; and Dr. H. Vihinen for help in confocal microscopy. This work was supported by grants from the Medical Research Council of the Academy of Finland, the Finnish Foundation for Cancer Research, the Jalmari and Rauha Ahokas Foundation, the Research and Science Foundation of Farmos, and the University of Helsinki.
| |
FOOTNOTES |
|---|
Corresponding author. E-mail address:
jorma.palvimo{at}helsinki.fi.
| |
REFERENCES |
|---|
|
|
|---|